WO2002072882A3 - Coronary chip - Google Patents

Coronary chip Download PDF

Info

Publication number
WO2002072882A3
WO2002072882A3 PCT/EP2002/002780 EP0202780W WO02072882A3 WO 2002072882 A3 WO2002072882 A3 WO 2002072882A3 EP 0202780 W EP0202780 W EP 0202780W WO 02072882 A3 WO02072882 A3 WO 02072882A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide sequences
hybridisation
coronary
chip
arteriosclerosis
Prior art date
Application number
PCT/EP2002/002780
Other languages
German (de)
French (fr)
Other versions
WO2002072882A2 (en
Inventor
Paul Cullen
Udo Seedorf
Original Assignee
Ogham Gmbh
Paul Cullen
Udo Seedorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogham Gmbh, Paul Cullen, Udo Seedorf filed Critical Ogham Gmbh
Priority to EP02702408A priority Critical patent/EP1368492A2/en
Publication of WO2002072882A2 publication Critical patent/WO2002072882A2/en
Publication of WO2002072882A3 publication Critical patent/WO2002072882A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The invention relates to a method for determining the genetic risk of arteriosclerosis, comprising the steps, selection of reference nucleotide sequences relevant to the risk of arteriosclerosis, including functional characteristic mutation thereof, application of probes of said nucleotide sequences or the complementary sequences thereof on a support, hybridisation of the probes with nucleotide sequences from a patient sample, or with nucleotide sequences synthesised from a patient sample, verification of the hybridisation and evaluation of the hybridisation.
PCT/EP2002/002780 2001-03-13 2002-03-13 Coronary chip WO2002072882A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02702408A EP1368492A2 (en) 2001-03-13 2002-03-13 Coronary chip

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111925A DE10111925A1 (en) 2001-03-13 2001-03-13 heart chip
DE10111925.9 2001-03-13

Publications (2)

Publication Number Publication Date
WO2002072882A2 WO2002072882A2 (en) 2002-09-19
WO2002072882A3 true WO2002072882A3 (en) 2003-10-02

Family

ID=7677213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002780 WO2002072882A2 (en) 2001-03-13 2002-03-13 Coronary chip

Country Status (3)

Country Link
EP (1) EP1368492A2 (en)
DE (1) DE10111925A1 (en)
WO (1) WO2002072882A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038265A1 (en) * 2004-09-30 2006-04-13 Yutaka Imauchi Medicinal composition for treating otospongiosis
FR2890859B1 (en) * 2005-09-21 2012-12-21 Oreal DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
EP2450444B1 (en) * 2006-11-30 2013-06-05 ARKRAY, Inc. Probe for analyzing a polymorphism in the beta2AR gene, reagent, and obesity gene analysis method
NZ592203A (en) * 2008-10-15 2013-01-25 Isis Pharmaceuticals Inc Modulation of factor 11 expression
BR112020020957B1 (en) 2018-05-09 2022-05-10 Ionis Pharmaceuticals, Inc Oligomeric compounds, population and pharmaceutical composition thereof and their uses
WO2023172783A2 (en) * 2022-01-07 2023-09-14 The Government Of The United States, As Represented By The Secretary Of The Army Hemostatic composition containing recombinant human clotting factors, and method of producing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011276A1 (en) * 1994-10-11 1996-04-18 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis and treatment of same using gene therapy
WO2001053520A2 (en) * 2000-01-21 2001-07-26 Paul Cullen Gene chip for neonate screening

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3704900A (en) * 1999-02-19 2001-02-05 University Of Iowa Research Foundation, The Diagnostics and therapeutics for macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011276A1 (en) * 1994-10-11 1996-04-18 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis and treatment of same using gene therapy
WO2001053520A2 (en) * 2000-01-21 2001-07-26 Paul Cullen Gene chip for neonate screening

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG SUZANNE ET AL: "A multilocus genotyping assay for candidate markers of cardiovascular disease risk.", GENOME RESEARCH, vol. 9, no. 10, October 1999 (1999-10-01), pages 936 - 949, XP002227081, ISSN: 1088-9051 *
HAYDEN M R ET AL: "MOLECULAR GENETICS OF HUMAN LIPOPROTEIN LIPASE DEFICIENCY", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 113, no. 2, 1992, pages 171 - 176, XP009003819, ISSN: 0300-8177 *
NAPOLI CLAUDIO ET AL: "Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray.", CIRCULATION. UNITED STATES 19 MAR 2002, vol. 105, no. 11, 19 March 2002 (2002-03-19), pages 1360 - 1367, XP009003926, ISSN: 1524-4539 *

Also Published As

Publication number Publication date
EP1368492A2 (en) 2003-12-10
DE10111925A1 (en) 2002-10-02
WO2002072882A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2005033335A3 (en) Microsensors and nanosensors for chemical and biological species with surface plasmons
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
WO1997018334A3 (en) Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits
WO2002018639A3 (en) Detection of cyp2c19 polymorphisms
WO2003016527A3 (en) Process for the detection of oxidative stress and kit for its implementation
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2007086980A3 (en) Methods of determining the risk of developing coronary artery disease
WO2003035671A3 (en) Methods for detecting genetic haplotypes by interaction with probes
WO2002072882A3 (en) Coronary chip
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1227676A3 (en) Method of selecting among multiply-categorised items
WO1999016780A3 (en) Genetic sequences, diagnostic and/or quantification methods for the identification of staphylococci strains
WO2001088189A3 (en) Microsatellite-aflp®
WO2008075977A3 (en) Methods and compositions for the assessment of cardiovascular function and disorders
AU2003292182A1 (en) Method for lowering both sequence variations and increase of base lines effects in diagnostic hybridisation assay, assay for performing such a method and probe for use in the assay
WO2005072152A3 (en) Apoc1 genetic markers associated with age of onset of alzheimer's disease
WO2004000995A3 (en) Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
WO1996041017A3 (en) Nucleic acid probes and amplification oligonucleotides for neisseria species
WO2003023056A3 (en) Specific markers for multiple sclerosis
WO2005002414A3 (en) Prognosis determination in ewing sarcoma patients by means of genetic profiling
WO2002076608A3 (en) Method for producing an array for detecting constituents from a biological sample
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002074987A3 (en) Quantitative diagnostic analysis of hypertonia
WO2005072150A3 (en) Ldlr genetic markers associated with age of onset of alzheimer's disease
AU2003276727A1 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002702408

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002702408

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002702408

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP